'I should have been scanned from the start' - a terminally ill woman faced a 13 month wait to learn she had breast cancer
A Belfast woman who has terminal cancer has said her outlook is worse due to the 13-month delay to be diagnosed.The mother of three had noticed changes to her breasts after childbirth and raised her concerns a number of times. She told BBC News NI she had months of symptoms.
In March, 48.1% of patients commenced their first treatment for cancer following an urgent referral within the 62 day target. At the end of March, 156,270 patients in Northern Ireland were waiting for a diagnostic test - a rise of 13.9% compared to the same quarter the previous year. A referral to the breast clinic also diagnosed mastitis and the IT consultant was told a scan was not possible as she was breastfeeding.
Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
Ceritinib is a novel triple negative breast cancer therapeutic agent - Molecular CancerBackground Triple-negative breast cancers (TNBCs) are clinically aggressive subtypes of breast cancer. TNBC is difficult to treat with targeted agents due to the lack of commonly targeted therapies within this subtype. Androgen receptor (AR) has been detected in 12–55% of TNBCs. AR stimulates breast tumor growth in the absence of estrogen receptor (ER), and it has become an emerging molecular target in TNBC treatment. Methods Ceritinib is a small molecule inhibitor of tyrosine kinase and it is used in the therapy of non-small lung cancer patients. Enzalutamide is a small molecule compound targeting the androgen receptor and it is used to treat prostate cancer. Combination therapy of these drugs were investigated using AR positive breast cancer mouse xenograft models. Also, combination treatment of ceritinib and paclitaxel investigated using AR− and AR low mouse xenograft and patient derived xenograft models. Results We screened 133 FDA approved drugs that have a therapeutic effect of AR+ TNBC cells. From the screen, we identified two drugs, ceritinib and crizotinib. Since ceritinib has a well- defined role in androgen independent AR signaling pathways, we further investigated the effect of ceritinib. Ceritinib treatment inhibited RTK/ACK/AR pathway and other downstream pathways in AR+ TNBC cells. The combination of ceritinib and enzalutamide showed a robust inhibitory effect on cell growth of AR+ TNBC cells in vitro and in vivo. Interestingly Ceritinib inhibits FAK-YB-1 signaling pathway that leads to paclitaxel resistance in all types of TNBC cells. The combination of paclitaxel and ceritinib showed drastic inhibition of tumor growth compared to a single drug alone. Conclusions To improve the response of AR antagonist in AR positive TNBC, we designed a novel combinational strategy comprised of enzalutamide and ceritinib to treat AR+ TNBC tumors through the dual blockade of androgen-dependent and androgen-independent AR signaling pathways. Furthermore, we introduced
Weiterlesen »
Breast cancer: 'I knew my body wasn't right''I knew my body wasn't right' Woman who has terminal cancer says her outlook is worse due to 13-month delay to be diagnosed
Weiterlesen »
Alesha Dixon heartbroken as beloved dog Daisy dies after 13 yearsBritain’s Got Talent judge Alesha Dixon has shared the devastating news that her dog Daisy has passed away aged 13, sparking people to send their condolences
Weiterlesen »
Breast milk donations requested by Western Health TrustA service that helps premature and seriously-ill babies across the island of Ireland has appealed for more breast milk donors.
Weiterlesen »